Company NurExone Biologic Inc. Deutsche Boerse AG
Equities
J90
CA67059R1091
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.448 EUR | +1.82% | +6.67% | +161.99% |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Lior Shaltiel
CEO | Chief Executive Officer | - | 31/03/21 |
Eran Ovadya
DFI | Director of Finance/CFO | - | 14/06/22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jay Richardson
BRD | Director/Board Member | 78 | 02/01/22 |
Gadi Riesenfeld
BRD | Director/Board Member | 79 | 05/07/23 |
Yoram Drucker
CHM | Chairman | 59 | 31/12/19 |
Oded Orgil
BRD | Director/Board Member | 57 | 14/06/22 |
Lior Shaltiel
CEO | Chief Executive Officer | - | 31/03/21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 67,162,428 | 63,740,695 ( 94.91 %) | 0 | 94.91 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.97% | 45.34B | |
+42.78% | 40.42B | |
-10.06% | 37.92B | |
+31.15% | 31.75B | |
-7.79% | 27.71B | |
+13.32% | 26.52B | |
+43.05% | 13.96B | |
+31.28% | 12.44B | |
-7.41% | 11.26B |
- Stock Market
- Equities
- NRX Stock
- J90 Stock
- Company NurExone Biologic Inc.